API-Bioxal 44.2 mg/ml Bee-Hive Solution

Oxalic Acid

Last verified

Veterinary medicinal product: bee-hive solution. Distribution category: AVM-GSL (Veterinary Medicines Regulations 2013, Schedule 3). Active substance: Oxalic Acid.1

In short: questions and answers

Does API-Bioxal 44.2 mg/ml Bee-Hive Solution need a prescription?
Over the counter. As stated in the registration decision.1
Which animals is API-Bioxal 44.2 mg/ml Bee-Hive Solution for?
Honey bees.1
What is the active substance in API-Bioxal 44.2 mg/ml Bee-Hive Solution?
Oxalic Acid. ATCvet code: QP53AG03.13
What is the withdrawal period of API-Bioxal 44.2 mg/ml Bee-Hive Solution according to the leaflet?
Honey bees, honey: 0 days.3
Dispensing
Over the counter1

AVM-GSL: Authorised Veterinary Medicine - General Sale List. No prescription is needed and it may be sold by any retailer.12

Supplied without a prescription. As stated in the registration decision.

Animal species
Honey bees1
Active substance
Oxalic Acid
ATCvet code
QP53AG033
Manufacturer
Marketing authorisation holder: Chemicals Laif S.P.A

Withdrawal period

Animal speciesProductdays
Honey beeshoney03
Summary of product characteristics

Composition

Each ml contains:

Active substance:

Oxalic acid 44.2 mg

(as oxalic acid dihydrate 62.0 mg)

Excipients:

For the full list of excipients, see section 6.1

6.1 List of excipients

Glycerol

Water, purified.

3

Pharmaceutical form

Bee-hive solution.

Clear colourless-light yellow liquid.

3

Pharmacological properties

Pharmacotherapeutic group: Ectoparasiticides for topical use, Incl. insecticides, organic acids, oxalic acid.

ATC Vet Code: QP53AG03.

5.1 Pharmacodynamic properties

Oxalic acid is an Organic acid. Oxalic acid is highly effective against phoretic varroa mites. Studies on the mode of action of oxalic acid have indicated that its low pH is a major contributor to the acaricidal effect. Oxalic acid has been shown to concentrate on mite legs and the edges of the exoskeleton, but none was detected in the alimentary system of mites. Therefore, mites are thought to receive the acid by contact.

5.2 Pharmacokinetic particulars

Oxalic acid, the active ingredient of the product, is a natural honey constituent and its concentration in honey depends on the botanical source. No increase of oxalic acid residues over the natural content of honey is to be expected as a consequence of proper product administration. After product treatments, oxalic acid distributes into the intestine and haemolymph of honeybees where its concentration rises temporarily.

When 4.2% oxalic acid (in 60% sucrose syrup) was administered by trickling, peak contamination of worker bees occurred within 4 days post-treatment, declining to 9% and 2% of the maximum value at 7 and 11 days post-treatment, respectively. Oxalic acid was detected in the alimentary system and haemolymph of bees.

3

Target species

Honey bees (Apis mellifera)

3

Indications

Treatment of varroosis caused by Varroa destructor in honey bees (Apis mellifera).

3

Dosage

In-hive use, the product must be used as follows:

Posology and method of administration by trickling:

The dosage required is 5 ml per seam (gap between top bars of frames) of bees. Maximal dose is 50 ml per hive. Up to two treatments per year (winter and/or spring-summer season in brood-free colonies).

The treatment should be made in a single administration. The product should be administered using a syringe along the length of each seam of bees.

3

Contraindications

None.

3

Adverse reactions

Target species: Honey bees (Apis mellifera)

FrequencyAdverse events
Very common (>1 colony/ 10 colonies treated):Slight agitation (during treatment); Increased adult bee mortality (after treatment)

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or the national competent authority via the national reporting system. See also the last section of the package leaflet for contact details.

3

Warnings

i). Special precautions for use in animals

Administer the treatment without supers. Avoid disturbance to the hives during the days after the treatment.

ii). Special precautions to be taken by the person administering the veterinary medicinal product to animals

This product is a highly acidic solution that may cause severe irritation to the skin and eyes. Avoid contact with the skin, eyes and mucous membranes. When handling the product wear protective clothing, chemical-resistant gloves, and safety glasses. After application, wash hands with soap and water and thoroughly wash any clothing that comes into contact with the product. In case of accidental spillage onto the skin, wash the affected areas immediately with running water. In case of accidental eye contacts, flush the eyes immediately with clear running water for 10 minutes.

Accidental ingestion may cause severe adverse reactions. Children should not come into contact with this veterinary medicinal product. In case of accidental ingestion, clean mouth with water and drink plenty of water or milk. Do not induce vomiting. Seek medical advice immediately.

Do not eat, drink or smoke while handling the product.

Special precautions for the protection of the environment: Not applicable.

iii). Other precautions

None

3

Use during pregnancy, lactation or lay

Not applicable.

3

Interactions

Do not use simultaneously with other acaricides.

3

Overdose

Significantly higher bee mortality was observed in hives that received by trickling a triple dosages of product. In addition, when overdosed, the over-wintering capacity of colonies was diminished and there may be detrimental effects on colony development in the future.

3

Special warnings

For greatest efficacy, the product should only be used when the quantity of brood in the colony is non-existent or at its lowest levels. Oxalic acid does not penetrate wax so will not kill mites within capped brood and therefore the presence of brood may noticeably reduce the efficacy of the product. As such, the product should be used in winter or following manipulation of the colony to produce a broodless state in summer (e.g. by queen caging).

With regard to summer treatments following queen caging, highest levels of efficacy were achieved when a caging period of at least 25 days was used, at which point the colonies were completely broodless. Despite proper treatment, seriously damaged colonies may not survive due to the effects of varroa infestation.

All colonies in the same apiary should be treated simultaneously to avoid reinfestations.

Integrated Pest Management Programme

The efficacy may vary between colonies due to the conditions of use (residue presence of brood, temperature, reinfestations etc.). The product should therefore be used as a treatment amongst others within an Integrated Pest Management program, and mite drop regularly monitored.

3

Withdrawal period

Honey: Zero days

Do not use in colonies with supers or during honey flow.'

3

Incompatibilities

In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products.

3

Immediate packaging

500 ml bottle: White opaque high-density polyethylene bottles with child – resistant screw cap (HDPE) and tamper-evident seal;

Available in pack sizes of 1 x 500 mL bottle

3

Storage

Do not refrigerate or freeze.

Store in the original package.

Keep the container tightly closed in order to protect from moisture.

3

Shelf life

Shelf life of the veterinary medicinal product as packaged for sale: 3 years.

Shelf life after first opening the immediate packaging: 12 months.

3

Disposal of unused product

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal product should be disposed of in accordance with local requirements.

API-Bioxal should not be allowed to contaminate water courses as this may be dangerous for fish and other aquatic organisms. The product should not be disposed of via wastewater.

3

Additional information

Vm 23101/5000

9 DATE OF FIRST AUTHORISATION

12 July 2023

10 DATE OF REVISION OF THE TEXT

July 2023

PROHIBITION OF SALE, SUPPLY AND/OR USE

Not applicable.

11 CLASSIFICATION OF VETERINARY MEDICINAL PRODUCTS

Veterinary medicinal product not subject to prescription.

Approved 12 July 2023

3

Registration holder

Chemicals Laif S.P.A

Viale dell'Artigianato 13

35010 Vigonza (PD)

Italy

3

Regulations

Sources

  1. VMD Product Information Database: API-Bioxal 44.2 mg/ml Bee-Hive Solution, 23101/5000 UK Veterinary Medicines Directorate (OGL v3.0), checked 2026-10-04 archived copy from 2026-10-04
  2. The Veterinary Medicines Regulations 2013, Schedule 3 (categories of veterinary medicinal products) UK Government, legislation.gov.uk, checked 2026-10-04 archived copy from 2026-10-04
  3. Summary of Product Characteristics: API-Bioxal 44.2 mg/ml Bee-Hive Solution UK Veterinary Medicines Directorate, SPC of the marketing authorisation holder, checked 2026-10-04 archived copy from 2026-10-04

Other products with the same active substance

All products with this active substance (4)

The same active substance in other countries

These are different medicines with different authorisations. The dispensing status is the one on each product's own page, which gives its basis. The leaflet of the product in hand applies.

Poland

All products with this active substance (3)